Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Merck
Mallinckrodt
Express Scripts
Baxter

Last Updated: June 30, 2022

CLINICAL TRIALS PROFILE FOR ANGIOMAX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Angiomax

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00043277 ↗ Study Of Angiomax In Infants Under Six Months With Thrombosis Completed The Medicines Company Phase 2 2002-08-01 The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2. To determine the dose of bivalirudin required to achieve adequate anticoagulation as measured by the activated clotting time (ACT) or activated partial thromboplastin time (aPTT) in Infants Under Six Months with arterial or venous thrombosis; 3. To determine the outcome of patients on bivalirudin with respect to thrombus resolution and bleeding complications compared to patients on unfractionated heparin (UH) or low molecular weight heparin (LMWH).
NCT00073580 ↗ Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE) Completed The Medicines Company Phase 3 2003-10-01 The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.
NCT00073593 ↗ Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB Completed The Medicines Company Phase 3 2003-08-01 The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.
NCT00079508 ↗ Angiomax in Patients With HIT/HITTS Type II Undergoing CPB Completed The Medicines Company Phase 3 2004-04-01 The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.
NCT00079586 ↗ Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) Completed The Medicines Company Phase 3 2004-04-01 The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Angiomax

Condition Name

Condition Name for Angiomax
Intervention Trials
Coronary Artery Bypass Surgery 4
Coronary Artery Disease 3
Thrombosis 2
Cardiovascular Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Angiomax
Intervention Trials
Myocardial Ischemia 4
Coronary Disease 4
Coronary Artery Disease 4
Thrombosis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Angiomax

Trials by Country

Trials by Country for Angiomax
Location Trials
United States 42
Canada 3
France 2
Netherlands 2
Czech Republic 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Angiomax
Location Trials
Ohio 6
New York 5
California 3
North Carolina 3
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Angiomax

Clinical Trial Phase

Clinical Trial Phase for Angiomax
Clinical Trial Phase Trials
Phase 4 4
Phase 3 10
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Angiomax
Clinical Trial Phase Trials
Completed 12
Terminated 3
Unknown status 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Angiomax

Sponsor Name

Sponsor Name for Angiomax
Sponsor Trials
The Medicines Company 11
Children's Hospital Los Angeles 1
Boston Scientific Corporation 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Angiomax
Sponsor Trials
Other 16
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
AstraZeneca
Mallinckrodt
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.